ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
Epidemiology and Risk Factors for Kidney Cancer.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers, 12 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
184 citing papers in PubMed, 12 syntheses or guidelines pooled it, 294 citations in OpenAlex.
- Occupational benzene exposure and risk of kidney and bladder cancers: a systematic review and meta-analysis.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2025Pooled it
- Diagnostic performance of artificial intelligence in detection of renal cell carcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Impact of pretreatment body mass index on clinical outcomes in patients with metastatic renal cell carcinoma receiving first-line immune checkpoint inhibitor-based therapy: A systematic review and meta-analysis.Investigative and clinical urology · 2024Pooled it
- Ambient air pollution and urological cancer risk: A systematic review and meta-analysis of epidemiological evidence.Nature communications · 2024Pooled it
- Per- and Poly-fluoroalkyl Substances (PFAS) Exposure and Risk of Kidney, Liver, and Testicular Cancers: A Systematic Review and Meta-Analysis.La Medicina del lavoro · 2023Pooled it
- First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.The Cochrane database of systematic reviews · 2023Pooled it
- Prognostic significance of albumin-to-globulin ratio in patients with renal cell carcinoma: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Is hysterectomy associated with kidney cancer risk? A meta-analysis of cohort studies.Frontiers in oncology · 2023Pooled it
- Circular RNAs as prognostic and diagnostic biomarkers in renal cell carcinoma.Journal of clinical laboratory analysis · 2022Pooled it
- Prognostic impact of prognostic nutritional index on renal cell carcinoma: A meta-analysis of 7,629 patients.PloS one · 2022Pooled it
- The Role of Chemokine Receptor CXCR3 and Its Ligands in Renal Cell Carcinoma.International journal of molecular sciences · 2020Pooled it
- The Relationship Between Hormone Replacement Therapy and Risk of Kidney Cancer in Women: A Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- A Web-Based Prediction Model for Cancer-Specific Survival of Middle-Aged Patients With Non-metastatic Renal Cell Carcinoma: A Population-Based Study.Frontiers in public health · 2022Trial
- HLA-G functions as a tumor-intrinsic driver of growth and survival in renal cell carcinoma.Oncoimmunology · 2026Article
- Limitations of evaluating risks of all cancers combined in etiological epidemiology research.Global epidemiology · 2026Article
- Global disparities in the availability and reimbursement of systemic therapies for renal cell carcinoma: results of the International ARON-AID Survey.The oncologist · 2026Article
- Biphasic CT clustering-based habitat radiomics predicts WHO/ISUP nuclear grade in clear cell renal cell carcinoma.Abdominal radiology (New York) · 2026Article
- Oncologic outcomes and renal function preservation after stereotactic ablative body radiotherapy versus radiofrequency ablation in stage I renal cell carcinoma.Clinical and translational radiation oncology · 2026Article
- Long-Term or Recurrent Antibiotic Use During Childhood or Adolescence and the Risk of Kidney Cancer: A Cohort Study.Cancer medicine · 2026Article
- Association Between Menopausal Hormone Therapy and the Risk of Urologic Cancer: A National Population-Based Retrospective Cohort Study in Korea.Journal of Korean medical science · 2026Article
124 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The purpose of this narrative review is to summarize evidence of the epidemiology of and risk factors for kidney cancer with a focus on renal cell carcinoma in adults. The etiology of kidney cancer is largely unknown and the main epidemiologic determinants are large geographic and temporal variations in incidence rates. Established risk factors include tobacco smoking, body size, and history of hypertension and chronic kidney disease. Other suspected risk factors require additional investigation, as do the underlying biologic mechanisms that are responsible for disease occurrence. Opportunities to prevent kidney cancer include targeting modifiable risk factors-for example, smoking abstinence/cessation and body weight control-as well as interventions along the diagnostic pathway to improve early diagnosis. Molecular epidemiology, including, but not limited to, metabolomics and tumor genomics, are new areas of research that promise to play important roles in identifying some of the underlying causes of kidney cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.